BioSpace News Archive

VBL Therapeutics will release its first quarter financial results for the period ended March 31, 2021 on Tuesday, May 11, 2021 before market open.

First-Quarter 2021 Revenues of $14.6 Billion, Reflecting 42% Operational Growth; Excluding Revenues for BNT162b2 of $3.5 Billion, Revenues Grew 8% Operationally Including a Negative 5% Impact from Pricing

Arvinas, Inc., a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that its first quarter 2021 financial results will be reported on Monday, May 17, 2021 after the close of the financial markets.

Neuronetics, Inc., a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced its financial and operating results for the first quarter of 2021.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced that the Company will present at the upcoming investor conferences:

Arch Biopartners Inc., a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced it has completed enrollment for its Phase II study of Metablok, targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19.

“Bausch Health entered 2021 with strong momentum as our recovery from the COVID-19 pandemic continues.

Motixafortide + G-CSF demonstrated a 4.9-fold increase versus G-CSF alone in achieving primary endpoint of target mobilization in up to TWO apheresis sessions

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it will release its first quarter 2021 financial results on Tuesday, May 11, after the close of the U.S. financial markets.